secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001193125-25-059327
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds
--------------------------------------------------------------------------------

- Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.
- Net proceeds ~$46.5M (or ~$53.6M if underwriters' option exercised in full).
- Underwriters granted 30-day option to purchase up to 3.75M additional shares.
- Expected closing March 21, 2025; Leerink Partners and Piper Sandler lead.
- Company states it is financed to achieve profitability under current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312525059327/0001193125-25-059327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312525059327/d908870d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-059327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer